Consumer Marketing briefs

Share this article:
A majority of doctors in a survey said pharmas should be prohibited from running TV ads promoting drugs for mental illnesses such as depression and anxiety. In a survey of 612 physicians by HCD Research using its site, 60% said TV ads for psych drugs should be disallowed.

Pharma ads are running much longer as FDA regulation of TV ads grows ever more stringent, a recent Bloomberg report noted, pointing to an increase in the amount of time devoted to risk information in ads for Pfizer's Chantix from 14 seconds to more than a minute, and to the fact that risk information now takes up half of a 30-second ad for Bristol-Myers Squibb's Plavix.
Pfizer consolidated media buying duties for consumer advertising on Wyeth brands into Carat, according to an Ad Age report, which estimated the worth of the business to be $250 million in billings. The business was previously handled in-house by Wyeth. Carat already held media buying and planning AOR status for Pfizer. TargetCast will continue to handle media planning on Wyeth consumer brands.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?